Previous studies have shown that BAFF is likely to have a role in the process of post-transplantation organ rejection, probably by acting on the process of B-cell maturation. Increased BAFF production ...
Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy. This is an ASCO Meeting ...
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell ...
B-cell activating factor receptor chimeric antigen receptor (CAR) T-cell therapy caused cytotoxic effects on all chronic lymphocytic leukemia (CLL) cell lines. “We hypothesized that BAFF-R CAR T-cell ...
Matsushita and colleagues [1] reported study findings of elevated serum levels of B-cell activating factor (BAFF), a potent B-cell survival factor, in 21 patients with systemic sclerosis (SSc). Sera ...
Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene Bio's PMB-102 Phase 1 study evaluating BAFF-R targeting CAR T cells (PMB-CT01) in adult ...
DUARTE, Calif.--(BUSINESS WIRE)--The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma ...
The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with ...
Nat Clin Pract Neurol. 2008;4(10):557-567. BCMA Stimulates plasma cell survival and IgM production TACI mRNA is upregulated in the brain and monocytes of patients with MS; TACI is produced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results